096760.KO Jw Holdings
- Market cap
- KRW 254B
- P/E
- 3.2x
- P/B
- 0.91x
- ROE
- 27.7%
- Dividend yield
- 7.31%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 096760.KO undervalued?
Graham number096760.KO trades 64.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jw Holdings fundamental analysis
No fundamental analysis for Jw Holdings yet.
Jw Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jw Holdings
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecologic…
Full company profileJw Holdings financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jw Holdings annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 680B | 684B | 725B | 726B | 782B | 789B | 865B | 928B | 888B | 970B | 1.02T |
| Gross Profit | 277B | 297B | 310B | 286B | 306B | 344B | 400B | 446B | 435B | 491B | 538B |
| Operating Income | 39.0B | 41.2B | 33.3B | 2.74B | 34.5B | 68.7B | 113B | 145B | 147B | 168B | 211B |
| EBITDA | - | 123B | 67.9B | 47.9B | 96.4B | 92.3B | 136B | 130B | 231B | 208B | 255B |
| Net Income | -8.66B | 54.0B | 23.2B | -33.4B | 10.7B | -2.78B | 22.2B | 19.0B | 62.6B | 58.5B | 80.2B |
| EPS | - | 807 | 346 | -504 | 161 | -40 | 307 | 263 | 886 | 846 | 1,159 |
| Balance Sheet | |||||||||||
| Total Assets | 1.20T | 1.35T | 1.28T | 1.24T | 1.12T | 1.07T | 1.16T | 1.18T | 1.25T | 1.23T | 1.28T |
| Total Liabilities | 919B | 977B | 875B | 892B | 784B | 761B | 824B | 828B | 729B | 637B | 630B |
| Shareholders' Equity | 117B | 168B | 182B | 150B | 146B | 93.2B | 107B | 124B | 230B | 267B | 290B |
| Cash & Short-term Investments | 53.2B | 41.6B | 74.5B | 116B | 30.7B | 46.9B | 60.5B | 73.9B | 44.0B | 71.8B | 75.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.2B | 10.5B | 196B | 98.7B | 109B | 110B | 104B | 112B | 97.9B | 164B | 191B |
| Capital Expenditure | 15.0B | 17.5B | 23.5B | 18.9B | 51.9B | 37.5B | 70.1B | 85.3B | 35.7B | 54.7B | 35.1B |
| Free Cash Flow | - | -15.2B | 170B | 71.3B | 51.1B | 66.1B | 34.3B | 27.0B | 62.2B | 109B | 155B |
| Ratios | |||||||||||
| ROE | -7.4% | 32.2% | 12.7% | -22.4% | 7.3% | -3.0% | 20.7% | 15.3% | 27.3% | 21.9% | 27.7% |
| ROA | -0.7% | 4.0% | 1.8% | -2.7% | 1.0% | -0.3% | 1.9% | 1.6% | 5.0% | 4.8% | 6.3% |
| Net Profit Margin | -1.3% | 7.9% | 3.2% | -4.6% | 1.4% | -0.4% | 2.6% | 2.1% | 7.1% | 6.0% | 7.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jw Holdings dividends
- Dividend yield
- 7.31%
- Forward dividend
- 215.00 KRW
- Payout ratio
- 31.7%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 18.5B | 268 | 31.7% |
| 2024 | KRW 17.2B | 243 | 27.4% |
| 2023 | KRW 17.7B | 246 | 93.2% |
| 2022 | KRW 15.4B | 213 | 69.6% |
| 2021 | KRW 14.5B | 211 | - |
| 2020 | KRW 16.0B | 241 | 149.9% |
| 2019 | KRW 15.6B | 236 | - |
| 2018 | KRW 21.6B | 322 | 93.2% |
| 2017 | KRW 10.2B | 152 | 18.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.02:1 on Dec 27, 2023.
Who owns Jw Holdings
- Insiders 54.19%
- Institutions 1.05%
- Public & others 44.76%
- Shares outstanding 69.2M
- Free float 35.9M
Jw Holdings company profile
- Company name
- Jw Holdings
- Ticker
- 096760.KO
- ISIN
- KR7096760004
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 114
- Fiscal year end
- December
- Address
- JW Gwacheon Tower, Gwacheon-si, South Korea, 13840
- Phone
- 82 2 8406 777
- Website
- jw-holdings.co.kr
About Jw Holdings
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecological examining table, sterilizer equipment, diagnostic imaging equipment, operating room equipment, non-PVC film, tube, and empty bag, and health supplements. In addition, the company provides integrated services for IV solution. JW Holdings Corporation was founded in 1945 and is based in Gwacheon-si, South Korea.
Jw Holdings management
5- Mr. Kyung-Ha LeeCEO & Chairman of the Board · born 1963
- Mr. Seongnam ChaCo-CEO & Internal Director
- Ji-Woo ChoiCFO & MD
- Eun-Kyung HamManaging Director
- Na Sook-heeInternal Director & Head of JW Management Planning Office